Latest Share Chat

REMOVE ADS

Glaxosmithkline Share News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes

Get Live Data

1,871.50 -41.50 (-2.17%)

Bid:

1,868.50

Ask:

1,870.00

Spread: 1.50 (0.08%)

Market Cap: £75.06b

Last checked at -

Intraday Glaxosmithkline Share Chart

REMOVE ADS

Glaxosmithkline News

LONDON MARKET CLOSE: Stocks end in green, US housing completions drop

(Alliance News) - Stock prices in London closed higher on Friday, with markets maintaining the optimism that prevailed after US President Donald Trump...

LONDON MARKET MIDDAY: FTSE 100 gain tempered as GSK tanks

(Alliance News) - Stock prices in Europe were largely higher at midday on Friday, though the FTSE 100 pared some earlier gains as a slump from GSK wei...

LONDON MARKET OPEN: FTSE 100 edges up; Reckitt rises on home care sale

(Alliance News) - Stock prices in Europe opened higher early on Friday, with the FTSE 100 almost hitting a new record high, as a swathe of dealmaking ...

FDA votes against overall benefit/risk profile of GSK's multiple myeloma candidate at proposed dosage

(Sharecast News) - Drugmaker GSK said on Friday that the US Food and Drug Administration's Oncologic Drugs Advisory Committee had voted against the ov...

Setback for GSK as Blenrep does not win US FDA committee support

(Alliance News) - GSK PLC on Thursday noted that the US Food & Drug Administration Oncologic Drugs Advisory Committee voted against the overall benefi...

GSK wins US approval for prefilled syringe version of shingles vaccine

(Alliance News) - GSK PLC on Thursday said the prefilled syringe version of its vaccine Shingrix has been approved for use in the US for the preventio...

US FDA approves new format of GSK's Shingrix

(Sharecast News) - GSK announced on Thursday that it has received approval from the US Food and Drug Administration for a new prefilled syringe presen...

Britain's life sciences plan gets mixed reception from pharma industry

Plan launched amid drug pricing disputes *